Sonesitatug Vedotin Improves OS in Gastroesophageal Cancer
Summary
The phase 3 trial found the greatest progression-free survival benefit in patients receiving third-line or later treatment, with fewer severe hematologic adverse events.
Description from Medscape.
Who is covering this
-
Sonesitatug Vedotin Improves OS in Gastroesophageal Cancer
The phase 3 trial found the greatest progression-free survival benefit in patients receiving third-line or later treatment, with fewer severe hematologic adverse events.
